Replies to post #123215 on Biotech Values

[drbio45]

from memory I think it is 2014

[biomaven0]

Repligen royalty:

The settlement further provides for Bristol to pay royalties on the United States net sales of Orencia® for any clinical indication at a rate of 1.8% for the first $500 million of annual net sales, 2.0% for the next $500 million of annual net sales and 4% of annual net sales in excess of $1 billion for each year from January 1, 2008 until December 31, 2013.

Repligen also owes 15% (I think) to some university.

Peter